DOCSLIB.ORG

Separately Chargeable Drugs List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

15 SEPTEMBER 2021 Separately Chargeable Drugs List Also known to customers as: List of specialist drugs Important information for providers only Listed below are the drugs which may be billed in addition to the charges that have been agreed as part of current hospital contracts. Drugs marked with * are those which may be charged separately when used as part of eligible treatment for cancer only. All separately chargeable drugs require pre-authorisation, we ask providers to call Bupa Provider Services on 0345 755 3333. Lines are open 9am to 5pm, Monday to Friday (calls may be recorded and may be monitored). Bupa Generic name (Brand name) Dosage, Cancer Pre- code formulation and only authorisation pack size required AD001 abciximab (ReoPro) 2mg/mL - 5mL vial No Yes injection AD002 aldesleukin (Interleukin-2) (Proleukin) 18million iu vial - Yes Yes powder for reconstitution AD006 alteplase (Actilyse) Powder for No Yes reconstitution - 20 mg (11.6 million units)/vial AD007 alteplase (Actilyse) 50 mg (29 million No Yes units)/vial injection AD008 alteplase (Actilyse) 10 mg (5.8 million No Yes units)/vial injection AD010 amphotericin (AmBisome) 50mg vial - powder No Yes for reconstitution AD011 amsacrine (Amsidine) 1.5mL (75mg) Yes Yes ampoule and 13.5mL diluent vial AD012 anagrelide (Xagrid) 100 x 500 mcg Yes Yes capsules AD013 anastrozole (Arimidex) 28 x 1mg tablets Yes Yes AD014 aprepitant (Emend) 2 x 80mg capsules Yes Yes AD015 aprepitant (Emend) 5 x 125mg capsules Yes Yes Please note that printed or downloaded versions of this document may be out of date. Bupa separately chargeable drugs list – 15 September 2021 Valid until 15 October 2021 © Bupa Insurance Services Limited 2021 15 SEPTEMBER 2021 Separately Chargeable Drugs List Also known to customers as: List of specialist drugs Bupa Generic name (Brand name) Dosage, Cancer Pre- code formulation and only authorisation pack size required AD016 aprepitant (Emend) 1 x 125mg capsule Yes Yes and 2 x 80mg capsules AD017 arsenic trioxide (Trisenox) 1mg/ml - 10mL Yes Yes ampoule for iv infusion AD018 azacitidine (Vidaza) 100mg vial injection - Yes Yes powder for reconstitution AD019 basiliximab (Simulect) 10mg vial injection - No Yes powder for reconsitution AD020 basiliximab (Simulect) 20mg vial injection - No Yes powder for reconsitution AD021 bendamustine hydrochloride (Levact) 25mg vial injection - Yes Yes powder for reconsitution AD022 bendamustine hydrochloride (Levact) 100mg vial injection - Yes Yes powder for reconsitution AD023 bevacizumab (Avastin) 25mg/mL - 16mL No Yes (400mg) vial for iv infusion AD024 bevacizumab (Avastin) 25mg/mL - 4mL No Yes (100mg) vial for iv infusion AD025 bexarotene (Targretin) 100 x 75mg capsules Yes Yes AD026 bicalutamide (Casodex) 28 x 50mg tablets Yes Yes AD027 bicalutamide (Casodex) 28 x 150mg tablets Yes Yes AD028 bivalirudin (Angiox) 250mg vial injection - No Yes powder for reconstitution AD029 bleomycin (Non Proprietary) 15,000 unit vial Yes Yes injection AD030 bortezomib (Velcade) 3.5mg vial injection - Yes Yes powder for reconstitution Please note that printed or downloaded versions of this document may be out of date. Bupa separately chargeable drugs list – 15 September 2021 Valid until 15 October 2021 © Bupa Insurance Services Limited 2021 15 SEPTEMBER 2021 Separately Chargeable Drugs List Also known to customers as: List of specialist drugs Bupa Generic name (Brand name) Dosage, Cancer Pre- code formulation and only authorisation pack size required AD031 botulinum A toxin (Botox) 100 unit vial injection No Yes AD032 botulinum A toxin (Botox) 200 unit vial injection No Yes AD033 botulinum A toxin (Botox) 50 unit vial injection No Yes AD034 botulinum A toxin (Dysport) 500 unit vial injection No Yes AD035 busulfan (Busilvex) 6mg/mL - 10mL vial Yes Yes concentrate for iv infusion AD036 buserelin (Suprefact) 1mg/ml - 2 x 5.5 ml Yes Yes vial injection AD037 buserelin (Suprefact) 100 mcg/metered Yes Yes spray - 4 x 10g bottle AD038 capecitabine (Xeloda) 60 x 150mg tablets Yes Yes AD039 capecitabine (Xeloda) 120 x 500mg tablets Yes Yes AD040 carboplatin (Non Proprietary) 10mg/mL - 15mL vial Yes Yes injection AD041 carboplatin (Non Proprietary) 10mg/mL - 45mL vial Yes Yes injection AD042 carboplatin (Non Proprietary) 10mg/mL - 5mL vial Yes Yes injection AD043 carboplatin (Non Proprietary) 10mg/mL - 60mL vial Yes Yes injection AD044 carmustine (Gliadel) 7.7mg implant Yes Yes AD045 caspofungin (Cancidas) 50mg vial - powder No Yes for iv infusion AD046 caspofungin (Cancidas) 70mg vial - powder No Yes for iv infusion AD047 cetuximab (Erbitux) 5mg/mL - 100mL vial Yes Yes for iv infusion AD048 cetuximab (Erbitux) 5mg/mL - 20mL vial Yes Yes for iv infusion AD049 chlorambucil (Leukeran) 25 x 2mg tablets Yes Yes AD050 chlorpromazine (Non Proprietary) 28 x 25mg tablets Yes Yes AD051 chlorpromazine (Non Proprietary) 28 x 50mg tablets Yes Yes AD052 chlorpromazine (Non Proprietary) 28 x 100mg tablets Yes Yes AD053 chlorpromazine (Non Proprietary) 25mg/5mL - 150mL Yes Yes oral solution Please note that printed or downloaded versions of this document may be out of date. Bupa separately chargeable drugs list – 15 September 2021 Valid until 15 October 2021 © Bupa Insurance Services Limited 2021 15 SEPTEMBER 2021 Separately Chargeable Drugs List Also known to customers as: List of specialist drugs Bupa Generic name (Brand name) Dosage, Cancer Pre- code formulation and only authorisation pack size required AD054 chlorpromazine (Non Proprietary) 100mg/5mL - 150mL Yes Yes oral solution AD055 chlorpromazine (Non Proprietary) 25mg/mL - 1mL Yes Yes ampoule injection AD056 chlorpromazine (Non Proprietary) 25mg/mL - 2mL Yes Yes ampoule injection AD057 cisplatin (Non Proprietary) 1mg/mL - 10mL vial Yes Yes injection AD058 cisplatin (Non Proprietary) 1mg/mL - 50mL vial Yes Yes injection AD059 cisplatin (Non Proprietary) 1mg/mL - 100mL vial Yes Yes injection AD065 cladribine (Leustat) 1mg/mL - 10mL vial Yes Yes injection AD066 clodronate (Bonefos) 120 x 400mg Yes Yes capsules AD067 clodronate (Bonefos) 60 x 800mg tablets Yes Yes AD068 clodronate (Loron 520) 60 x 520mg tablets Yes Yes AD069 clofarabine (Evoltra) 1 mg/mL, 20mL vial Yes Yes AD070 crisantaspase (Erwinase) 10 000 unit vial Yes Yes powder for reconstitution AD071 cyclophosphamide (Non Proprietary) 100 x 50mg tablets Yes Yes AD072 cyclophosphamide (Non Proprietary) 500mg vial injection - Yes Yes powder for reconstitution AD073 cyclophosphamide (Non Proprietary) 1g vial injection - Yes Yes powder for reconstitution AD074 cyproterone acetate (Cyprostat) 168 x 50mg tablets Yes Yes AD075 cyproterone acetate (Cyprostat) 80 x 100mg tablets Yes Yes AD076 cytarabine (DepoCyte) 50mg vial intrathecal Yes Yes injection AD077 cytarabine (Non Proprietary) 20mg/mL- 5mL vial Yes Yes intrathecal injection Please note that printed or downloaded versions of this document may be out of date. Bupa separately chargeable drugs list – 15 September 2021 Valid until 15 October 2021 © Bupa Insurance Services Limited 2021 15 SEPTEMBER 2021 Separately Chargeable Drugs List Also known to customers as: List of specialist drugs Bupa Generic name (Brand name) Dosage, Cancer Pre- code formulation and only authorisation pack size required AD078 cytarabine (Non Proprietary) 20 mg/mL - 5mL vial Yes Yes iv or subcutaneous injection AD079 cytarabine (Non Proprietary) 20 mg/mL - 25mL vial Yes Yes iv or subcutaneous injection AD080 cytarabine (Non Proprietary) 100 mg/mL - 1mL vial Yes Yes iv or subcutaneous injection AD081 cytarabine (Non Proprietary) 100 mg/mL - 5mL vial Yes Yes iv or subcutaneous injection AD082 cytarabine (Non Proprietary) 100 mg/mL - 10mL Yes Yes vial iv or subcutaneous injection AD083 cytarabine (Non Proprietary) 100 mg/mL - 20mL Yes Yes vial iv or subcutaneous injection AD084 dacarbazine (Non Proprietary) 100mg vial injection - Yes Yes powder for reconstitution AD085 dacarbazine (Non Proprietary) 200mg vial injection - Yes Yes powder for reconstitution AD086 dacarbazine (Non Proprietary) 500mg vial injection - Yes Yes powder for reconstitution AD088 dacarbazine (Non Proprietary) 1g vial injection - Yes Yes powder for reconstitution AD089 dactinomycin (Cosmegen Lyovac) 0.5mg vial injection - Yes Yes powder for reconstitution AD090 dasatinib (Sprycel) 60 x 20mg tablets Yes Yes AD091 dasatinib (Sprycel) 60 x 50mg tablets Yes Yes AD093 dasatinib (Sprycel) 60 x 100mg tablets Yes Yes Please note that printed or downloaded versions of this document may be out of date. Bupa separately chargeable drugs list – 15 September 2021 Valid until 15 October 2021 © Bupa Insurance Services Limited 2021 15 SEPTEMBER 2021 Separately Chargeable Drugs List Also known to customers as: List of specialist drugs Bupa Generic name (Brand name) Dosage, Cancer Pre- code formulation and only authorisation pack size required AD094 daunorubicin (Non Proprietary) 20mg vial injection - Yes Yes powder for reconstitution AD095 daunorubicin lipid form (DaunoXome 50mg vial - Yes Yes (liposomal daunorubicin)) concentrate for iv infusion AD096 dexrazoxane (Cardioxane) 500mg vial - powder Yes Yes for iv infusion AD097 dexrazoxane (Savene) 10 x 500mg vials - Yes Yes powder for iv infusion AD098 dibotermin alfa (InductOs) 1.5mg/mL - 10mL vial No Yes - powder for reconstitution AD099 diethylstilbestrol (Non Proprietary) 28 x 1mg tablets Yes Yes AD100 diethylstilbestrol (Non Proprietary) 28 x 5mg tablets Yes Yes AD101 disodium pamidronate (Aredia) 15mg vial injection - Yes Yes powder for reconstitution AD102 disodium pamidronate (Aredia) 30mg vial injection - Yes Yes
Recommended publications
  • Fludarabine, Treosulfan and Etoposide Sensitivity and the Outcome of Hematopoietic Stem Cell Transplantation in Childhood Acute Myeloid Leukemia

    Fludarabine, Treosulfan and Etoposide Sensitivity and the Outcome of Hematopoietic Stem Cell Transplantation in Childhood Acute Myeloid Leukemia

    ANTICANCER RESEARCH 27: 1547-1552 (2007) Fludarabine, Treosulfan and Etoposide Sensitivity and the Outcome of Hematopoietic Stem Cell Transplantation in Childhood Acute Myeloid Leukemia JAN STYCZYNSKI1, JACEK TOPORSKI2, MARIUSZ WYSOCKI1, ROBERT DEBSKI1, ALICJA CHYBICKA2, DARIUSZ BORUCZKOWSKI3, JACEK WACHOWIAK3, BEATA WOJCIK4, JERZY KOWALCZYK4, LIDIA GIL5, WALENTYNA BALWIERZ6, MICHAL MATYSIAK7, MARYNA KRAWCZUK-RYBAK8, ANNA BALCERSKA9 and DANUTA SONTA-JAKIMCZYK10 1Department of Pediatric Hematology and Oncology, Medical College, Nicolaus Copernicus University, ul. Curie-Sklodowskiej 9, 85-094 Bydgoszcz; 2Department of Pediatric Transplantology, Hematology and Oncology, Medical University, ul. Bujwida 44, 50-345 Wroclaw; 3Department of Pediatric Transplantology, Hematology and Oncology, Medical University, ul. Szpitalna 27/33, 60-572 Poznan; 4Department of Pediatric Hematology and Oncology, Medical University, ul. Chodzki 2, 20-093 Lublin; 5Department of Hematology, Medical University, ul. Szamarzewskiego 84, 60-569 Poznan; 6Department of Pediatric Oncology/Hematology, Medical College, Jagiellonian University, ul. Wielicka 265, 30-663 Krakow; 7Department of Pediatric Hematology and Oncology, Medical University, ul. Marszalkowska 24, 00-576 Warsaw; 8Department of Pediatric Hematology and Oncology, Medical University, ul. Waszyngtona 17, 15-274 Bialystok; 9Department of Pediatric Hematology, Oncology and Endocrinology, Medical University, ul. Debinki 7, 80-210 Gdansk; 10Department of Pediatric Hematology and Oncology, Medical University, ul.
  • PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

    PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

    International Journal of Molecular Sciences Review PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects Rosalin Mishra , Hima Patel, Samar Alanazi , Mary Kate Kilroy and Joan T. Garrett * Department of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267-0514, USA; [email protected] (R.M.); [email protected] (H.P.); [email protected] (S.A.); [email protected] (M.K.K.) * Correspondence: [email protected]; Tel.: +1-513-558-0741; Fax: +1-513-558-4372 Abstract: The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted. Keywords: cancer; PIK3CA; resistance; PI3K inhibitors Citation: Mishra, R.; Patel, H.; Alanazi, S.; Kilroy, M.K.; Garrett, J.T.
  • Nanomedicines and Combination Therapy of Doxorubicin and Olaparib for Treatment of Ovarian Cancer

    Nanomedicines and Combination Therapy of Doxorubicin and Olaparib for Treatment of Ovarian Cancer

    Nanomedicines and Combination Therapy of Doxorubicin and Olaparib for Treatment of Ovarian Cancer by Sina Eetezadi A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Pharmaceutical Sciences University of Toronto © Copyright by Sina Eetezadi 2016 Nanomedicines and Combination Therapy of Doxorubicin and Olaparib for Treatment of Ovarian Cancer Sina Eetezadi Doctor of Philosophy Department of Pharmaceutical Sciences University of Toronto 2016 Abstract Ovarian cancer is the fourth leading cause of death in women of developed countries, with dismal survival improvements achieved in the past three decades. Specifically, current chemotherapy strategies for second-line treatment of relapsed ovarian cancer are unable to effectively treat recurrent disease. This thesis aims to improve the therapeutic outcome associated with recurrent ovarian cancer by (1) creating a 3D cell screening method as an in vitro model of the disease (2) developing a nanomedicine of doxorubicin (DOX) that is more efficacious than PEGylated liposomal doxorubicin (PLD / Doxil®) and (3) evaluating additional strategies to enhance treatment efficacy such as mild hyperthermia (MHT) and combination therapy with inhibitors of the poly(ADP-ribose) polymerase enzyme family (PARP). Overall, this work demonstrates the use of 3D multicellular tumor spheroids (MCTS) as an in vitro drug testing platform which more closely reflects the clinical presentation of recurrent ovarian cancer relative to traditional monolayer cultures. With the use of this technology, it was found that tissue penetration of drug is not only an issue for large tumors, but also for invisible, microscopic lesions that result from metastasis or remain following cytoreductive surgery. A novel block-copolymer micelle formulation for DOX was developed and fulfilled the goal of ii controlling drug release while enhancing intratumoral distribution and MCTS bioavailability of DOX, which resulted in a significant improvement in growth inhibition, relative to PLD.
  • Genetic Screens in Isogenic Mammalian Cell Lines Without Single Cell Cloning

    Genetic Screens in Isogenic Mammalian Cell Lines Without Single Cell Cloning

    ARTICLE https://doi.org/10.1038/s41467-020-14620-6 OPEN Genetic screens in isogenic mammalian cell lines without single cell cloning Peter C. DeWeirdt1,2, Annabel K. Sangree1,2, Ruth E. Hanna1,2, Kendall R. Sanson1,2, Mudra Hegde 1, Christine Strand 1, Nicole S. Persky1 & John G. Doench 1* Isogenic pairs of cell lines, which differ by a single genetic modification, are powerful tools for understanding gene function. Generating such pairs of mammalian cells, however, is labor- 1234567890():,; intensive, time-consuming, and, in some cell types, essentially impossible. Here, we present an approach to create isogenic pairs of cells that avoids single cell cloning, and screen these pairs with genome-wide CRISPR-Cas9 libraries to generate genetic interaction maps. We query the anti-apoptotic genes BCL2L1 and MCL1, and the DNA damage repair gene PARP1, identifying both expected and uncharacterized buffering and synthetic lethal interactions. Additionally, we compare acute CRISPR-based knockout, single cell clones, and small- molecule inhibition. We observe that, while the approaches provide largely overlapping information, differences emerge, highlighting an important consideration when employing genetic screens to identify and characterize potential drug targets. We anticipate that this methodology will be broadly useful to comprehensively study gene function across many contexts. 1 Genetic Perturbation Platform, Broad Institute of MIT and Harvard, 75 Ames Street, Cambridge, MA 02142, USA. 2These authors contributed equally: Peter C. DeWeirdt,
  • The Role of PARP1 in Monocyte and Macrophage

    The Role of PARP1 in Monocyte and Macrophage

    cells Review The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors Maciej Sobczak 1, Marharyta Zyma 2 and Agnieszka Robaszkiewicz 1,* 1 Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; [email protected] 2 Department of Immunopathology, Medical University of Lodz, 7/9 Zeligowskiego, Bldg 2, Rm177, 90-752 Lodz, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-42-6354449; Fax: +48-42-6354449 or +48-42-635-4473 Received: 4 August 2020; Accepted: 4 September 2020; Published: 6 September 2020 Abstract: Modulation of PARP1 expression, changes in its enzymatic activity, post-translational modifications, and inflammasome-dependent cleavage play an important role in the development of monocytes and numerous subtypes of highly specialized macrophages. Transcription of PARP1 is governed by the proliferation status of cells at each step of their development. Higher abundance of PARP1 in embryonic stem cells and in hematopoietic precursors supports their self-renewal and pluri-/multipotency, whereas a low level of the enzyme in monocytes determines the pattern of surface receptors and signal transducers that are functionally linked to the NFκB pathway. In macrophages, the involvement of PARP1 in regulation of transcription, signaling, inflammasome activity, metabolism, and redox balance supports macrophage polarization towards the pro-inflammatory phenotype (M1), which drives host defense against pathogens. On the other hand, it seems to limit the development of a variety of subsets of anti-inflammatory myeloid effectors (M2), which help to remove tissue debris and achieve healing.
  • PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide

    PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide

    Published OnlineFirst October 5, 2015; DOI: 10.1158/1535-7163.MCT-15-0587 Cancer Biology and Signal Transduction Molecular Cancer Therapeutics PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway Florian Engert1, Cornelius Schneider1, Lilly Magdalena Weib1,2,3, Marie Probst1,and Simone Fulda1,2,3 Abstract Ewing sarcoma has recently been reported to be sensitive to that subsequent to DNA damage-imposed checkpoint activa- poly(ADP)-ribose polymerase (PARP) inhibitors. Searching for tion and G2 cell-cycle arrest, olaparib/TMZ cotreatment causes synergistic drug combinations, we tested several PARP inhibi- downregulation of the antiapoptotic protein MCL-1, followed by tors (talazoparib, niraparib, olaparib, veliparib) together with activation of the proapoptotic proteins BAX and BAK, mitochon- chemotherapeutics. Here, we report that PARP inhibitors syner- drial outer membrane permeabilization (MOMP), activation of gize with temozolomide (TMZ) or SN-38 to induce apoptosis caspases, and caspase-dependent cell death. Overexpression of a and also somewhat enhance the cytotoxicity of doxorubicin, nondegradable MCL-1 mutant or BCL-2, knockdown of NOXA or etoposide, or ifosfamide, whereas actinomycin D and vincris- BAX and BAK, or the caspase inhibitor N-benzyloxycarbonyl-Val- tine show little synergism. Furthermore, triple therapy of ola- Ala-Asp-fluoromethylketone (zVAD.fmk) all significantly reduce parib, TMZ, and SN-38 is significantly more effective compared olaparib/TMZ-mediated apoptosis. These findings emphasize with double or monotherapy. Mechanistic studies revealed that the role of PARP inhibitors for chemosensitization of Ewing the mitochondrial pathway of apoptosis plays a critical role in sarcoma with important implications for further (pre)clinical mediating the synergy of PARP inhibition and TMZ.
  • The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity Daniel A.R

    The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity Daniel A.R

    Published OnlineFirst October 22, 2018; DOI: 10.1158/1078-0432.CCR-18-0277 Cancer Therapy: Preclinical Clinical Cancer Research The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity Daniel A.R. Heisey1, Timothy L. Lochmann1, Konstantinos V. Floros1, Colin M. Coon1, Krista M. Powell1, Sheeba Jacob1, Marissa L. Calbert1, Maninderjit S. Ghotra1, Giovanna T. Stein2, Yuki Kato Maves3, Steven C. Smith4, Cyril H. Benes2, Joel D. Leverson5, Andrew J. Souers5, Sosipatros A. Boikos6, and Anthony C. Faber1 Abstract Purpose: It was recently demonstrated that the EWSR1-FLI1 revealed increased expression of the antiapoptotic protein t(11;22)(q24;12) translocation contributes to the hypersensi- BCL-2 in the chemotherapy-resistant cells, conferring apo- tivity of Ewing sarcoma to PARP inhibitors, prompting clinical ptotic resistance to olaparib. Resistance to olaparib was evaluation of olaparib in a cohort of heavily pretreated Ewing maintained in this chemotherapy-resistant model in vivo, sarcoma tumors. Unfortunately, olaparib activity was disap- whereas the addition of the BCL-2/XL inhibitor navitoclax pointing, suggesting an underappreciated resistance mecha- led to tumor growth inhibition. In 2 PDXs, olaparib and nism to PARP inhibition in patients with Ewing sarcoma. We navitoclax were minimally effective as monotherapy, yet sought to elucidate the resistance factors to PARP inhibitor induced dramatic tumor growth inhibition when dosed in therapy in Ewing sarcoma and identify a rational drug com- combination. We found that EWS-FLI1 increases BCL-2 bination capable of rescuing PARP inhibitor activity. expression; however, inhibition of BCL-2 alone by veneto- Experimental Design: We employed a pair of cell lines clax is insufficient to sensitize Ewing sarcoma cells to ola- derived from the same patient with Ewing sarcoma prior to parib, revealing a dual necessity for BCL-2 and BCL-XL in and following chemotherapy, a panel of Ewing sarcoma cell Ewing sarcoma survival.
  • And Nano-Based Transdermal Delivery Systems of Photosensitizing Drugs for the Treatment of Cutaneous Malignancies

    And Nano-Based Transdermal Delivery Systems of Photosensitizing Drugs for the Treatment of Cutaneous Malignancies

    pharmaceuticals Review Micro- and Nano-Based Transdermal Delivery Systems of Photosensitizing Drugs for the Treatment of Cutaneous Malignancies Isabella Portugal 1, Sona Jain 1 , Patrícia Severino 1 and Ronny Priefer 2,* 1 Programa de Pós-Graduação em Biotecnologia Industrial, Universidade Tiradentes, Aracaju 49032-490, Brazil; [email protected] (I.P.); [email protected] (S.J.); [email protected] (P.S.) 2 Massachusetts College of Pharmacy and Health Sciences, University, Boston, MA 02115, USA * Correspondence: [email protected] Abstract: Photodynamic therapy is one of the more unique cancer treatment options available in today’s arsenal against this devastating disease. It has historically been explored in cutaneous lesions due to the possibility of focal/specific effects and minimization of adverse events. Advances in drug delivery have mostly been based on biomaterials, such as liposomal and hybrid lipoidal vesicles, nanoemulsions, microneedling, and laser-assisted photosensitizer delivery systems. This review summarizes the most promising approaches to enhancing the photosensitizers’ transdermal delivery efficacy for the photodynamic treatment for cutaneous pre-cancerous lesions and skin cancers. Additionally, discussions on strategies and advantages in these approaches, as well as summarized challenges, perspectives, and translational potential for future applications, will be discussed. Citation: Portugal, I.; Jain, S.; Severino, P.; Priefer, R. Micro- and Keywords: photodynamic therapy; drug delivery; transdermal; cutaneous; cancer Nano-Based Transdermal Delivery Systems of Photosensitizing Drugs for the Treatment of Cutaneous Malignancies. Pharmaceuticals 2021, 1. Introduction 14, 772. https://doi.org/10.3390/ ph14080772 In past decades, clinical demands for the utilization of photosensitizers (PSs) have increased with the advent of photodynamic therapy (PDT).
  • AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
  • Bonviva, INN- Ibandronic Acid

    Bonviva, INN- Ibandronic Acid

    European Medicines Agency London, 1 September 2005 Doc.Ref.: EMEA/278873/2005 Bonviva International Nonproprietary Name: Ibandronic acid Following the procedure EMEA/H/C/501/X/01 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: [email protected] http://www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged 1 SCIENTIFIC DISCUSSION 1.1 Introduction and rationale The MAH submitted an extension application under Annex II, point 2 iii to Commission Regulation (EC) No 1085/2003 to request the approval of a 150 mg tablet as a monthly dosing regimen of ibandronate only for the indication of “treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures”. This claim is based on the results of a phase III study MOBILE (BM16549) comparing 100 and 150 mg once monthly to 2.5 mg once daily. Due to the inconveniences associated with intake of oral bisphosphonates (i.e. fasting conditions, frequent upper gastrointestinal intolerance) that may result in poor compliance, it was considered desirable to develop a more convenient drug formulation. Hence a 150 mg once monthly oral regimen is expected to offer greater convenience to postmenopausal women when compared to the currently approved 2.5mg once daily tablet. The development programme No new pre-clinical pharmacodynamic and pharmacokinetic studies have been performed in addition to those included in the previous submission for ibandronate 2.5 mg daily oral tablets.
  • CCA Senior Care Options Formulary

    CCA Senior Care Options Formulary

    Commonwealth Care Alliance Senior Care Option HMO SNP 2021 List of Covered Drugs Formulary 30 Winter Street • Boston, MA 02108 PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN This formulary was updated on 08/01/2021. For more recent information or other questions, please contact Senior Care Options Program (HMO SNP) Member Services, at 1-866-610-2273 or, for TTY users, 711, 8 a.m. – 8 p.m., 7 days a week, or visit www.commonwealthcaresco.org. HPMS Approved Formulary File Submission ID 00021589, Version Number 13 Senior Care Options Program (HMO SNP) 2021 Formulary (List of Covered Drugs) PLEASE READ: THIS DO CUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS Approved Formulary File Submission ID 00021589, Version Number 13 Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us”, or “our,” it means Commonwealth Care Alliance. When it refers to “plan” or “our plan,” it means 2021 Senior Care Options Program. This document includes list of the drugs (formulary) for our plan which is current as of 08/01/2021. This formulary document applies to all SCO members. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy n etwork, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.
  • Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers

    Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers

    Published OnlineFirst June 12, 2020; DOI: 10.1158/2159-8290.CD-20-0163 RESEARCH ARTICLE Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers Timothy A. Yap1,2, Rebecca Kristeleit3, Vasiliki Michalarea1, Stephen J. Pettitt4,5, Joline S.J. Lim1, Suzanne Carreira2, Desamparados Roda1,2, Rowan Miller3, Ruth Riisnaes2, Susana Miranda2, Ines Figueiredo2, Daniel Nava Rodrigues2, Sarah Ward1,2, Ruth Matthews1,2, Mona Parmar1,2, Alison Turner1,2, Nina Tunariu1, Neha Chopra1,4, Heidrun Gevensleben2, Nicholas C. Turner1,4, Ruth Ruddle2, Florence I. Raynaud2, Shaun Decordova2, Karen E. Swales2, Laura Finneran2, Emma Hall2, Paul Rugman6, Justin P.O. Lindemann6, Andrew Foxley6, Christopher J. Lord4,5, Udai Banerji1,2, Ruth Plummer7, Bristi Basu8, Juanita S. Lopez1,2, Yvette Drew7, and Johann S. de Bono1,2 Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Published OnlineFirst June 12, 2020; DOI: 10.1158/2159-8290.CD-20-0163 ABSTRACT Preclinical studies have demonstrated synergy between PARP and PI3K/AKT path- way inhibitors in BRCA1 and BRCA2 (BRCA1/2)–deficient andBRCA1/2 -proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective intrapatient dose- escalation design to assess two schedules of capivasertib (AKT inhibitor) with olaparib (PARP inhibi- tor) in 64 patients with advanced solid tumors. Dose expansions enrolled germline BRCA1/2-mutant tumors, or BRCA1/2 wild-type cancers harboring somatic DNA damage response (DDR) or PI3K–AKT pathway alterations. The combination was well tolerated. Recommended phase II doses for the two schedules were: olaparib 300 mg twice a day with either capivasertib 400 mg twice a day 4 days on, 3 days off, or capivasertib 640 mg twice a day 2 days on, 5 days off.